Cidara reports Q2 net loss $25.7M; Phase 2b influenza trial met endpoints; closed $402.5M offering

Cidara Therapeutics, Inc.

2025-Q2 EPS reported -$3.31

Primary endpoint met: CD388 doses (150-450mg) showed 57.7-76.1% protection vs placebo over 24 weeks.
Closed $402.5M public offering at $44/share; cash balance $516.9M as of June 30, 2025.
Net loss $25.7M for Q2 2025 vs $91.2M in Q2 2024 (includes $84.9M IPR&D charge in prior year).
R&D expenses rose to $24.8M from $6.7M YoY due to Phase 2b and Phase 3 preparation costs.
End of Phase 2 meeting request submitted to FDA; plan to initiate Phase 3 in spring 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.